StockMarketWire.com - Cell-based therapeutics developer ReNeuron Group said it would partner with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform.

The grant had been awarded under Innovate UK's Knowledge Transfer Partnership and would fund a £250k collaborative programme of research, to be undertaken by ReNeuron and the European Cancer Stem Cell Research Institute at Cardiff University.

The research programme would develop novel systems to enable the delivery of therapeutic nucleic acids, such as small interfering RNA, across the blood brain barrier using ReNeuron's CTX stem cell-derived exosomes.

'We and our collaborators are delighted to have won this latest grant from Innovate UK,' head of research Randolph Corteling said.

'We are very excited about the potential of our exosome technology platform to deliver therapeutic compounds to the brain and thereby to make a real step-change in the development of treatments against hard-to-target disorders of the central nervous system.'




Story provided by StockMarketWire.com